The Journal of Immunology, Vol 153, Issue 11 5176-5182, Copyright © 1994 by American Association of Immunologists

ARTICLES

Abnormal signal transduction by T cells of mice with parental tumors is not seen in mice bearing IL-2-secreting tumors

S Salvadori, B Gansbacher, AM Pizzimenti and KS Zier
Division of Clinical Immunology, Mount Sinai School of Medicine, New York, NY 10029.

There is considerable evidence to demonstrate that immune function is abnormal in tumor-bearing mice, perhaps accounting, at least in part, for progressive tumor growth. In an attempt to generate an antitumor response, we used retroviral vectors to express IL-2 cDNA in CMS5, a murine fibrosarcoma. Mice inoculated with unmodified tumor cells suffered progressive tumor growth, whereas tumors secreting IL-2 were rejected or grew slowly. Animals bearing unmodified but not IL-2- secreting tumors also were immunosuppressed. On the basis of these observations, we were interested in how IL-2 secretion by the tumor cells prevented the onset of hyporesponsiveness. To identify biochemical differences between T cells of mice with parental vs slowly growing IL-2-secreting tumors, we examined signal transduction after activation through the CD3/TCR complex. Protein tyrosine phosphorylation was altered and calcium flux was reduced in cells of mice with parental tumors compared with animals with slowly growing IL- 2-secreting tumors. In addition, levels of protein for the tyrosine kinases p56lck and p59fyn, as well as the TCR-zeta-chain, were reduced. These differences in signal transduction were observed for T cells of mice with parental and IL-2-secreting tumors of the same size, demonstrating that differences in tumor size alone could not explain our findings. Thus, IL-2 secretion by tumors seems to be able to prevent immunosuppression by maintaining normal signal transduction in T cells, facilitating the generation of antitumor responses.

This article has been cited by other articles:

				D. I. Gabrilovich, M. P. Velders, E. M. Sotomayor, and W. M. Kast Mechanism of Immune Dysfunction in Cancer Mediated by Immature Gr-1+ Myeloid Cells J. Immunol., May 1, 2001; 166(9): 5398 - 5406. [Abstract] [Full Text] [PDF]

				S. Radoja, T. D. Rao, D. Hillman, and A. B. Frey Mice Bearing Late-Stage Tumors Have Normal Functional Systemic T Cell Responses In Vitro and In Vivo J. Immunol., March 1, 2000; 164(5): 2619 - 2628. [Abstract] [Full Text] [PDF]

				S. Salvadori, G. Martinelli, and K. Zier Resection of Solid Tumors Reverses T Cell Defects and Restores Protective Immunity J. Immunol., February 15, 2000; 164(4): 2214 - 2220. [Abstract] [Full Text] [PDF]

				C. Maccalli, P. Pisarra, C. Vegetti, M. Sensi, G. Parmiani, and A. Anichini Differential Loss of T Cell Signaling Molecules in Metastatic Melanoma Patients' T Lymphocyte Subsets Expressing Distinct TCR Variable Regions J. Immunol., December 15, 1999; 163(12): 6912 - 6923. [Abstract] [Full Text] [PDF]

				A. E. Annenkov, S. P. Moyes, Z. Eshhar, R. A. Mageed, and Y. Chernajovsky Loss of Original Antigenic Specificity in T Cell Hybridomas Transduced with a Chimeric Receptor Containing Single-Chain Fv of an Anti-Collagen Antibody and Fc{epsilon}RI-Signaling {gamma} Subunit J. Immunol., December 15, 1998; 161(12): 6604 - 6613. [Abstract] [Full Text] [PDF]

				W. Ling, P. Rayman, R. Uzzo, P. Clark, H. J. Kim, R. Tubbs, A. Novick, R. Bukowski, T. Hamilton, and J. Finke Impaired Activation of NFkappa B in T Cells From a Subset of Renal Cell Carcinoma Patients Is Mediated by Inhibition of Phosphorylation and Degradation of the Inhibitor, Ikappa Balpha Blood, August 15, 1998; 92(4): 1334 - 1341. [Abstract] [Full Text] [PDF]

				H. Luo, H. Chen, S. Qi, D. Loh, P. Daloze, A. Veillette, D. Xu, and J. Wu De Novo-Developed T Cells Have Compromised Response to Existing Alloantigens: Using Ld-Specific Transgenic 2C T Cells as Tracers in a Mouse Heart Transplantation Model J. Immunol., July 1, 1998; 161(1): 73 - 82. [Abstract] [Full Text] [PDF]

				C. J. Fitzer-Attas, D. G. Schindler, T. Waks, and Z. Eshhar Harnessing Syk Family Tyrosine Kinases as Signaling Domains for Chimeric Single Chain of the Variable Domain Receptors: Optimal Design for T Cell Activation J. Immunol., January 1, 1998; 160(1): 145 - 154. [Abstract] [Full Text] [PDF]

				A. Guarini, L. Riera, A. Cignetti, L. Montacchini, M. Massaia, and R. Foa Transfer of the Interleukin-2 Gene Into Human Cancer Cells Induces Specific Antitumor Recognition and Restores the Expression of CD3/T-Cell Receptor Associated Signal Transduction Molecules Blood, January 1, 1997; 89(1): 212 - 218. [Abstract] [Full Text] [PDF]